Conversely, Chiang et al. found that mTOR signalling contributes to metabolic reprogramming in erlotinib (EGFR inhibitor) resistant lung cancer cells and strongly correlates with poor clinical outcomes of EGFR-mutated lung cancer patients [96]. The gene discussed is MTOR; the disease is lung carcinoma.